

STD Case Counts

Table 1: King County ST[morhidity	§		
Table 1. King County 311	2015 201 5		2016	
	2015Q1	YTD	2016Q1	YTD
Gonorrhea (GC)	664	664	848	848
GC: MSM*	322	322	419	419
Urethral GC	118	118	123	123
Rectal GC	137	137	182	182
Pharyngeal GC	140	140	198	198
GC: Women^	188	188	232	232
GC: MSW^†	120	120	130	130
Chlamydia (CT)	2052	2052	2393	2393
CT: MSM	373	373	483	483
Urethral CT	112	112	153	153
Rectal CT	237	237	311	311
CT: Women^	1151	1151	1297	1297
CT: MSW^	360	360	422	422
Syphilis‡	147	147	148	148
Primary and secondary	51	51	63	63
Early latent	44	44	50	50
Late + unk duration	52	52	35	35
Early syphilis: MSM	88	88	100	100
Early syphilis: Women	1	1	4	4
E syphilis: MSW	1	1	3	3
Congenital syphilis	0	0	0	0

§ 5 cases of GC, CT & syphilis reported in transgender persons in YTD 2016

‡ Total cases (all stages)

Trends in STD Morbidity





Table 2: King County newly diagnosed HIV cases*							
	20	2014		2015			
	2014Q4	YTD	2015Q4	YTD			
Total^	51	272	60	237			
MSM	35	186	38	160			
Women	6	39	11	31			
MSW	1	11	6	17			
Transgender**	1	4	0	2			

^{*} Data shown for prior quarter due to reporting delay

Trends in STD Morbidity



^{*} Men who have sex with men


[†] Men who have sex with women


[^] Genital tract infection

[^] Column may not equal total due to missing sexual preference data

^{**}Transgender identity relies on review of information documented in medical records and obtained through Partner Services Interviews. Data presented here are a potential undercount.








HIV testing should be performed annually on low-risk MSM and quarterly on high-risk MSM^a.

Figure 5: Expedited Partner Therapy (EPT) among King County women and MSW diagnosed with GC or CT



All women and MSW diagnosed with gonorrhea or chlamydia

should be offerred EPT by their diagnosing provider.

Footnotes:


^aHigh-risk = MSM with any one of the following in the prior year: diagnosis of a bacterial STD, methamphetamine or popper use, ≥10 sex partners (anal or oral), or unprotected anal sex with a partner of unknown or discordant HIV status Low-risk = sexually active MSM who do not meet high-risk criteria

^bGonococcal Isolate Surveillance Project (GISP), source of antibiotic susceptibility data, is supported by the Centers for Disease Control and Prevention

^cAlert values:


Ceftriaxone MIC \geq 0.125 µg/ml Cefixime MIC \geq 0.25 µg/ml Azithromycin MIC \geq 2.0 µg/ml





Anyone diagnosed with a bacterial STD should be tested for HIV.

Figure 6: Percentage of male GISP^b urethral isolates with alert values for cephalosporins or azithromycin (note scales)



Alert value = Minimum Inhibitory Concentration (MIC, lowest antibiotic concentration needed to halt bacterial growth) is higher than preset thresholds^c. Alert value MICs represent decreased susceptibility to an antibotic but may not represent resistance.

Table 3: Male GISP urethral isolates with alert values for cephalosporins or azithromycin^d

	2015		2016	
	2015Q1	YTD	2016Q1	YTD
Total isolates tested*	48	48	51	51
MSM	41	41	35	35
MSW	7	7	4	4
Total alert isolates*	4	4	7	7
MSM - ceph	1	1	5	5
MSM - azi	3	3	1	1
MSW - ceph	0	0	0	0
MSW - azi	0	0	0	0

* Column may not equal total due to missing sexual preference data

d3 rectal cefixime alert & 1 pharyngeal cefixme alerts identified Jan-Mar 2016